Phaseline

Companies › Biojiva

Biojiva: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Ophthalmology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Botulinum Toxin Type A (RT001)
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
SNAP25Phase 2Infantile Neuroaxonal Dystrophy–
BRX011–Phase 1Geographic AtrophyApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03570931Botulinum Toxin Type A (RT001)Phase 2Infantile Neuroaxonal DystrophyMetabolic and endocrineAug 2020
NCT07029945BRX011Phase 1Geographic AtrophyOphthalmologyApr 2029

Targets

SNAP25 (1)

Companies with the same targets

AbbVie Merz Therapeutics Ipsen Huons Biopharma Merz Aesthetics Merz Pharmaceuticals Merz North America

Companies built like this

Nacuity Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Sling Therapeutics Aptabio Therapeutics PolyActiva

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.